Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 17/20 | 0.81 |
| ▸ | IDH2 | P48735 | 9/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29763251 | 1.00 | IDH1 (0.81) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL18510340 | 0.96 | IDH1 (0.75) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL15102466 | 0.96 | IDH1 (0.81) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL21573339 | 0.91 | IDH1 (0.68) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL15102454 | 0.91 | IDH1 (0.74) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL29763354 | 0.91 | IDH1 (0.74) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL29660732 | 0.91 | IDH1 (0.79) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL15102328 | 0.91 | IDH1 (0.74) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL15102617 | 0.90 | IDH1 (0.67) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL18781059 | 0.89 | IDH1 (0.71) | IDH1IDH2ABCB11ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4647076-A2 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier (FR) | 2025-11-12 | — | — | EP | disclosed |
| EP-3984997-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER LAB (FR) | 2025-07-30 | — | — | EP | disclosed |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220348554-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2022-11-03 | — | — | US | disclosed |
| CN-107641114-B | Compound as isocitrate dehydrogenase inhibitor and application thereof | 南京圣和药业股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-109890806-B | Compound as isocitrate dehydrogenase inhibitor and application thereof | 南京圣和药业股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20170044139-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170044139-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
| US-9512107-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512107-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-11-03 | — | — | US | disclosed |
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-11-03 | — | — | US | disclosed |
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-11-03 | — | — | US | disclosed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013102431-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348554-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, MMP8 | IDH1 456/4885IDH2 203/4885ABCB11 2681/4885 |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
| US-20170044139-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885ABCB11 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.